BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

...require additional clinical studies, according to the company.Anti-OX40L mAb meets in dermatitis Phase II KY1005, an anti-OX40L...
...dermatitis. TARGETSANGPTL3 - Angiopoietin-like 3BCMA (TNFRSF17; CD269) – Tumor necrosis factor receptor superfamily member 17OX40L (CD134L) – OX40 ligand BC...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...from Moderna Inc. (NASDAQ:MRNA) was similarly disappointing. Data from a Phase I/II trial showed the OX40 ligand...
...OX40 (TNFRSF4; CD134) - Tumor necrosis factor (TNF) receptor superfamily member 4 OX40L (CD134L) - OX40 ligand Stephen...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

...of its cancer programs with Phase I/II data for mRNA-2416, a nanoparticle encapsulated mRNA encoding OX40L...
...protein 4 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 OX40L (CD134L) - OX40 ligand...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

...planning a global Phase II trial. SCB-340 and SCB-333, trimer tagged versions of TNF proteins OX40L...
...President: Peng Liang Patents: Undisclosed Targets 4-1BBL (TNFSF9; CD137L) - 4-1BB ligand OX40L (CD134L) - OX40 ligand...
...Inc. Sichuan Clover Biopharmaceuticals Inc. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 4-1BB ligand (4-1BBL) (TNFSF9) (CD137L) OX40 ligand (OX40L) (CD134L) Tumor...
BioCentury | Feb 22, 2020
Translation in Brief

Storm's open-access algorithm for RNA epigenetics; plus Duke studies show checkpoint blockers promote anti-HIV bNAbs and reduce opioid efficacy

Algorithm from Storm and academic collaborators for high-throughput analysis of RNA epigenetics Storm Therapeutics Ltd. and collaborators at the University of Pennsylvania and the University of Tübingen have created a computational algorithm, Nucleic Acid Search...
BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

Elpiscience hopes a $100 million series B round led by Hyfinity Investments will enable the company to expand its immuno-oncology pipeline and provide enough runway to carry it to an IPO, Ming Fang, head of...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BioCentury | Sep 18, 2019
Distillery Therapeutics

Preventing glial cell graft rejection with a T cell-targeting immunotherapy

...Baltimore, Md. email: pwalczak@mri.jhu.edu Hongjiang Li Johns Hopkins University Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) OX40 ligand (OX40L) (CD134L) CD40...
Items per page:
1 - 10 of 113